| |
Aripiprazole |
Dehydro-aripiprazole |
| |
Aripiprazole 5 mg (Reference) |
Desvenlafaxine 100 mg + Aripiprazole 5 mg (Test) |
Aripiprazole 5 mg (Reference) |
Desvenlafaxine
100 mg + Aripiprazole 5 mg (Test) |
| N, n |
38, 37 |
35, 35 |
38, 18 |
35, 14 |
| AUCinf (ng•h/mL)* |
1494 (43) |
1604 (33) |
695.9 (21) |
685.8 (21) |
| Cmax (ng/mL)* |
24.66 (29) |
24.69 (29) |
3.007 (34) |
3.185 (30) |
| tmax (h)† |
3.00 (2.00-8.00) |
4.00 (2.00-8.00) |
59.9 (23.9-120) |
71.9 (23.9-168) |
| t½ (h)‡ |
85.17 (26) |
84.18 (24) |
97.78 (17) |
94.27 (17) |
AUCinf= area under the plasma concentration curve over infinite time; Cmax = peak plasma concentration; N= number of subjects in the treatment group; n= number of subjects
where AUCinf was determined for aripiprazole, and where t½ and AUCinf were determined for dehydro-aripiprazole; t½ = half-life; tmax = time to peak plasma concentration
*Geometric mean (geometric %CV)
†Median (range)
‡Arithmetic mean (%CV) |
